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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the risk of "other substances" in food supplements and energy drinks sold in 
Norway. VKM has assessed the risk of doses in food supplements and concentrations in 
energy drinks given by NFSA. These risk assessments will provide NFSA with the scientific 
basis while regulating the addition of "other substances" to food supplements and other 
foods. 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect. It is added 
mainly to food supplements, but also to energy drinks and other foods. VKM has not in this 
series of risk assessments of "other substances" evaluated any claimed beneficial effects 
from these substances, only possible adverse effects. 
The present report is a risk assessment of specified doses of L-aspartic acid in food 
supplements, and it is based on previous risk assessments and articles retrieved from 
literature searches. 
According to information from NFSA, L-aspartic acid is an ingredient in food supplements 
sold in Norway. NFSA has requested a risk assessment of 3000, 3500, 4000, 4500, 5000 and 
5700 mg/day of L-aspartic acid in food supplements. 
L-aspartic acid is a dispensable dicarboxylic amino acid that can be produced by the 
transamination of oxaloacetic acid, an intermediate in the metabolism of e.g. glucose and 
some amino acids. L-aspartic acid is present in frequently consumed foods of animal and 
plant origin and is also a component of the sweetener aspartame. Dietary intake of aspartic 
acid in Norway is not known, but data from NHANES III (USA) suggest a mean dietary intake 
of about 6.5 g/day in adults. The highest intake was seen in men 31 through 50 years of age 
at the 99th percentile of 15.4 g/day. 
In the literature review we did not identify any long-term studies in human individuals that 
could be used for risk assessment. Short-term human studies found no adverse health effect 
when L-aspartic acid was given in acute doses ranging from 1 to 10 g/day, for time periods 
between one single dose and four weeks. None of these studies were undertaken to assess 
the toxicity of L-aspartic acid.  
In the literature search, two animal studies were identified of which one was a 90-day 
subchronic toxicity study. In that study, a no observed adverse effect level (NOAEL) of 
697 mg/kg bw per day in male rats and 715 mg/kg bw per day in female rats was 
established. No neurotoxicity was found, however a toxic effect on kidneys and possibly 
salivary glands was observed at 1400 mg/kg bw per day (lowest observed adverse effect 
level, LOAEL). For the risk characterisation, the NOAEL of 697 mg/kg bw per day derived 
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from the abovementioned subchronic toxicity study in rats was used for comparison with the 
estimated exposures from food supplements. The calculated Margin of Exposure (MOE) 
values for this NOAEL ranged from 5 to 16 for a daily intake of 3000-5700 mg/day of L-
aspartic acid. These low MOE-values may not be regarded as acceptable since L-aspartic acid 
has caused toxic effects on the kidneys (regenerative renal tubules with tubular dilation) and 
acinar cell hypertrophy of salivary glands in rats. Further, direct information regarding 
potential adverse health effects in humans is not available due to absence of long-term 
studies.  
In adults (≥18 years), adolescents (14 to < 18 years) and children (10 to < 14 years), the 
specified doses 3000, 3500, 4000, 4500, 5000 and 5700 mg/day L-aspartic acid in food 
supplements may represent a risk of adverse health effects.  
Children younger than 10 years were not within the scope of the present risk assessment. 
Short summary 
At the request of the Norwegian Food Safety Authority, the Norwegian Scientific Committee 
for Food Safety (VKM) has characterised the risk of specified doses of L-aspartic acid in food 
supplements. VKM concludes that: 
In adults (≥18 years), adolescents (14 to < 18 years) and children (10 to < 14 years), the 
specified doses 3000, 3500, 4000, 4500, 5000 and 5700 mg/day L-aspartic acid in food 
supplements may represent a risk of adverse health effects.  
Key words: L-aspartic acid, aspartate, food supplement, adverse health effect, negative 
health effect, Norwegian Food Safety Authority, Norwegian Scientific Committee for Food 
Safety, other substances, risk assessment, VKM 
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Sammendrag på norsk 
På oppdrag for Mattilsynet har Vitenskapskomiteen for mattrygghet (VKM) vurdert risiko ved 
tilsetting av «andre stoffer» i kosttilskudd og energidrikk som selges i Norge. VKM har 
risikovurdert ulike doser brukt av kosttilskudd og konsentrasjoner i energidrikker oppgitt fra 
Mattilsynet. Disse risikovurderingene vil gi Mattilsynet vitenskapelig grunnlag for å regulere 
andre stoffer. 
«Andre stoffer» er beskrevet i kosttilskuddsdirektivet 2002/46/EC som stoffer som har en 
ernæringsmessig og/eller fysiologisk effekt, og som ikke er vitaminer og mineraler. De 
tilsettes i hovedsak til kosttilskudd, men også til energidrikker og andre næringsmidler. I 
disse risikovurderingene har VKM ikke sett på påståtte gunstige helseeffekter, men kun 
vurdert mulige negative helseeffekter. 
Denne rapporten er en risikovurdering av L-aspartat, og den er basert på tidligere 
risikovurderinger og artikler hentet fra litteratursøk.  
I følge informasjon fra Mattilsynet er L-aspartat en ingrediens i kosttilskudd som selges i 
Norge. Oppdraget fra Mattilsynet var å risikovurdere inntak på 3000, 3500, 4000, 4500, 5000 
and 5700 mg/dag L-aspartat i kosttilskudd. 
L-aspartat er en ikke-essensiell aminosyre med to karboksylgrupper. Den dannes ved 
transaminering av oksaleddiksyre, en metabolitt i omsetningen av bl.a. glukose og enkelte 
aminosyrer. L-aspartat finnes i en rekke vanlige matvarer av både animalsk og vegetabilsk 
opprinnelse, og er også en bestanddel i søtstoffet aspartam. Det finnes ikke data på inntaket 
av L-aspartat fra kosten i Norge, men data fra USA (NHANES III) viser et gjennomsnittlig 
inntak på 6,5 g/dag hos voksne. Blant men 31-50 år hadde 99% et inntak på 15,4 g/dag 
eller lavere. 
I litteraturgjennomgangen ble det ikke avdekket noen langtidsstudier med mennesker som 
var egnet for bruk i risikovurdering av L-aspartat. Det er ikke rapportert om negative 
helseeffekter fra kortvarige humanstudier med doser fra 1 til 10 g L-aspartat, og varighet fra 
en enkelt dose opp til 4 uker. Ingen av disse korttidsstudiene hadde imidlertid som hovedmål 
å avdekke negative helseeffekter.  
Det ble funnet to dyrestudier i litteratursøket. En av disse var en 90 dagers subkronisk 
toksisitetsstudie. I denne studien ble det etablert en NOAEL (no observed adverse effect 
level) på 697 mg/kg kroppsvekt per dag i hannrotter og 715 mg/kg kroppsvekt per dag i 
hunnrotter. Nevrotoksiske funn har blitt beskrevet før, men ble ikke funnet i denne studien, 
det ble imidlertid observert toksiske effekt på nyrer og spyttkjertler ved en dose på 
1400 mg/kg kroppsvekt per dag (LOAEL – lowest observed adverse effect level). I VKMs 
risikokarakterisering av L-aspartat er NOAEL-verdien på 697 mg/kg kroppsvekt per dag lagt 
til grunn og vurdert opp mot de alternative dosene fra kosttilskudd.  
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De beregnede verdiene for "margin of exposure" (MOE-verdiene) er i området 5 til 16 for de 
spesifiserte dosene i kosttilskudd på 3000 til 5700 mg/dag av L-aspartat. 
Disse lave MOE-verdiene kan ikke anses som akseptable ettersom L-aspartat har forårsaket 
toksiske effekter på nyrene (regenerative nyretubuli med tubulær utvidelse) og hypertrofi av 
acinære celler i spyttkjertler hos rotter. Mulige negative helseeffekter hos mennesker er 
heller ikke kjent på grunn av mangelen på langtidsstudier. 
Vitenskapskomiteen for mattrygghet (VKM) konkluderer med at:  
 For voksne (≥18 år), ungdom (14 til <18 år) og barn (10 til <14 år) vil dosene 3000, 
3500, 4000, 4500, 5000 og 5700 mg/dag L-aspartat i kosttilskudd kunne 
representere en risiko for negative helseeffekter.  
Barn under 10 år inngår ikke i oppdraget. 
Kort sammendrag: 
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag fra Mattilsynet vurdert risiko ved 
inntak av spesifikke doser av aminosyren L-aspartat i kosttilskudd. VKM konkluderer med at 
dosene 3000, 3500, 4000, 4500, 5000 og 5700 mg/dag L-aspartat i kosttilskudd vil kunne 
representere en risiko for negative helseeffekter hos voksne (≥18 år), ungdom (14 til <18 
år), og barn (10 til <14 år). 
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Abbreviations and glossary 
Abbreviations 
AESAN  - Spanish Agency for Food Safety and Nutrition 
AFSSA  - French Food Safety Agency 
ANSES  - French Agency for Food, Environmental and Occupational Health and Safety 
bw  - body weight 
EFSA  - European Food Safety Authority 
JECFA  - Joint FAO/WHO Expert Committee on Food Additives 
IOM  - Institute of Medicine, USA 
LOAEL  - lowest observed adverse effect level 
MOE  - Margin of exposure 
NFSA  - Norwegian Food Safety Authority [Norw.: Mattilsynet] 
NHANES - National Health and Nutrition Examination Survey 
NOAEL  - no observed adverse effect level 
PLP  - pyridoxal phosphate 
SCF  - Scientific Committee on Food 
UL  - tolerable upper intake level 
VKM  - Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
WHO  - World Health Organization 
XAG  - Na(+)-dependent glutamate transport system 
Glossary 
"Other substances": a substance other than a vitamin or mineral that has a nutritional or 
physiological effect (European Regulation (EC) No. 1925/2006, Article 2; http://eur-
lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1925&from=en).  
"Negative health effect" and "adverse health effect" are broad terms. VKM uses the definition 
endorsed by EFSA for "adverse effect": a change in morphology, physiology, growth, 
development, reproduction or life span of an organism, system or (sub)population that 
results in an impairment of functional capacity, an impairment of the capacity to compensate 
for additional stress, or an increase in susceptibility to other influences (EFSA, 2006; WHO, 
1994). 
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Background as provided by the 
Norwegian Food Safety Authority 
“Other substances” are substances other than vitamins and minerals, with a nutritional 
and/or physiological effect on the body. "Other substances" are mainly added to food 
supplements, but these may also be added to other foods and beverages, such as sports 
products and energy drinks. Ingestion of these substances in high amounts presents a 
potential risk for consumers. 
In Norway, a former practice of classification of medicines had constituted an effective 
barrier against the sale of potentially harmful "other substances". Ever since this practice 
was changed in 2009, it has become challenging to regulate and supervise foods with added 
"other substances". Meanwhile, in the recent years, the Norwegian market has witnessed a 
marked growth in the sales of products containing "other substances". In 2011, food 
supplements containing "other substances" constituted more than 50% of the market share. 
While within the European Economic Area, these substances fall under the scope of the 
European Regulation (EC) No. 1925/2006 on the addition of vitamins, minerals and certain 
other substances to foods and the European Regulation (EC) No 258/97 concerning novel 
foods and novel food ingredients, "other substances" remain largely unregulated. In order to 
ensure safe use of "other substances" many countries have regulated their use at a national 
level. For example, Denmark regulates these substances in a positive list i.e. a list of 
substances with maximal daily doses, permitted for use in food supplements and other foods 
(FVM, 2014).  
The Norwegian Food Safety Authority (NFSA) is working on the establishment of a regulation 
on the addition of "other substances" to foods at a national level. The regulation will include 
a list of substances with permitted maximal doses, based on the substances and doses found 
in products on the Norwegian market. In preparation for a regulation, NFSA has therefore 
requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the safety of 
"other substances" found on the Norwegian market. NFSA, in consultation with the industry, 
has compiled a list of "other substances" found in products marketed in Norway. Only 
substances with a purity of minimum 50% or concentrated 40 times or more have been 
included in the list. Substances regulated by other legislations like those for novel foods, 
food additives, flavourings, foods for special medical purposes etc., have been excluded from 
the list.   
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA) has requested the Norwegian Scientific 
Committee for Food Safety (VKM) to assess the safety of L-aspartic acid in food supplements 
at the following doses: 3000, 3500, 4000, 4500, 5000 and 5700 mg/day. 
NFSA requested VKM to assess the safety of "other substances" (in accordance to the 
guidance document developed in Phase 2) at the doses specified (Phase 3). The safety 
assessments of "other substances" present in food supplements shall be carried out for a 
general population, ages 10 years and above.  
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Assessment 
1 Introduction 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect, and may 
be added to food supplements or e.g. energy drinks. 
This risk assessment regards the substance L-aspartic acid (aspartate) per se, and no 
specific products. 
VKM has in this series of risk assessments of "other substances" not evaluated 
documentation of any claimed beneficial effects from these substances, but merely possible 
adverse effects at specified doses used in Norway.  
According to information from the Norwegian Food Safety Authority (NFSA), L-aspartic acid 
is an ingredient in food supplements purchased in Norway. NFSA has requested a risk 
assessment of the intake of 3000, 3500, 4000, 4500, 5000 and 5700 mg L-aspartic acid per 
day from food supplements. The total L-aspartic acid exposure from other sources than food 
supplements, such as foods and cosmetic products, is not included in the risk assessment. A 
dietary requirement for aspartic acid in healthy humans has not been estimated since it is 
not considered an essential nutrient. According to the third US National Health and Nutrition 
Examination Survey (NHANES III, 1988-1994), the overall mean intake of L-aspartic acid 
from food and food supplements in the United States was 6.5 g/day. 
L-aspartic acid is a dispensable dicarboxylic amino acid that can be produced by the 
transamination of oxaloacetic acid, an intermediate in the metabolism of e.g. glucose and 
amino acids. 
L-aspartic acid is a constituent of most proteins and peptides synthesised in the body. In 
adults, most of the ingested L-aspartic acid is used as an energy fuel (2.3 kcal/g). L-aspartic 
acid is also used for the synthesis of L-asparagine, pyrimidine and purine nucleotides, and 
the neurotransmitter N-methyl D-aspartate (Kohlmeier, 2015).  
All foods contain significant amount of L-aspartic acid, thus total protein intake is a major 
determinant of L-aspartic acid intake. The additive aspartame, used as a sweetener, is an 
exogenous source of L-aspartic acid, as it metabolises into aspartic acid, phenylalanine and 
methanol (AESAN, 2015). Aspartame contains about 40% aspartic acid (IOM, 2005). 
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2 Hazard identification and 
characterisation 
2.1 Literature 
This risk assessment is based on previous risk assessments of L-aspartic acid, as well as 
scientific papers retrieved from two systematic literature searches: one search in literature 
published before 21 October 2016 aiming at retrieving human studies on adverse effects 
caused by L-aspartic acid, and one search in literature published before 8 November 2016 
aiming at retrieving animal model studies on toxicity of L-aspartic acid. 
 Previous risk assessments 
Risks related to L-aspartic acid have previously been evaluated by the Institute of Medicine 
(IOM), USA, 2005, and by the Scientific Committee of the Spanish Agency for Food Safety 
and Nutrition (ASEAN), Spain, 2015. An opinion from EFSA (2013) concerning aspartame as 
a food additive, also contained information on aspartic acid, and a review of the most 
important information is presented at the end of this chapter.   
Table 2.1.1-1: Overview of previous risk assessments of L-aspartic acid. 
Risk assessment 
body, country, 
publication year 
Objective Conclusion Suggested doses 
IOM, USA, 2005 To establish dietary 
reference intakes and 
identify potential adverse 
effects of L-aspartic acid 
and other nutrients 
Data were not available 
for dose-response 
assessment and 
derivation of a UL for L-
aspartic acid in apparently 
healthy humans 
Dietary supplement doses of 
up to 8 g/d (approximately 
120 mg/kg body weight/d) 
have not resulted in any 
documented adverse effects 
ASEAN, Spain, 
2015 
To assess the use of L-
aspartic acid as a food 
supplement 
Considering the NOAEL of 
700 mg/kg/day and using 
an uncertainty factor of 
100, the ADI (Acceptable 
Daily Intake) is 7 
mg/kg/day 
A maximum daily quantity of 
490 mg/d of L-aspartic is 
acceptable from the safety 
point of view for use as a food 
supplement 
Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, 
Cholesterol, Protein, and Amino Acids from Institute of Medicine (IOM). USA, 
2005 
According to the IOM (2005), all human studies on the effects of aspartic acid were of short 
duration (acute doses ranging from 1 to 10 g/day, for time periods between one single dose 
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and four weeks). These studies found no adverse health effect, when L-aspartic acid was 
given in acute doses up to 10 g. There are two subchronic studies with duration up to 13 
weeks on the oral administration of aspartame to humans (Frey, 1976; Knopp et al., 1976); 
however, in both studies no dose-response data were available. The IOM noted that dietary 
supplement doses up to 8 g/day (approximately 120 mg/kg bw per day) of L-aspartic acid 
had not resulted in any documented adverse effects. However, the IOM concluded that there 
were insufficient scientific data to develop a tolerable upper intake level (UL) for aspartic 
acid, due to lack of dose-response data.  
According to the IOM (2005), all animal studies on the effects of aspartic acid involved acute 
exposures. The most serious endpoint identified in animal studies was the development of 
neuronal necrosis in the hypothalamus of newborn rodents after oral administration of 
aspartic acid a few days postpartum. Neuronal necrosis in the hypothalamus was not found 
in newborn non-human primates with levels of plasma dicarboxylic amino acids 10 times 
those found in newborn mice with neuronal necrosis (Stegink, 1976; Stegink et al., 1974). In 
view of the scientific debate regarding the sensitivity of newborn animals to the consumption 
of supplemental dicarboxylic amino acids, it was concluded that aspartic acid dietary 
supplements were not advisable for infants and pregnant women.  
Report of the Scientific Committee of the Spanish Agency for Food Safety and 
Nutrition (AESAN) on the use conditions for certain substances other than 
vitamins, minerals and plants in food supplements. Spain, 2015. 
According to AESAN (2015), excess L-aspartic acid may cause neurotoxicity, in particular 
hypothalamic lesions in newborn rodents (Schainker and Olney, 1974; Tada et al., 2008) 
carried out a subchronic toxicity study in rats, in which the authors established a no 
observed adverse effect level (NOAEL) for female rats of 715.2 mg/kg bw per day and of 
696.6 mg/kg bw per day for male rats. Considering the NOAEL of 696.6 mg/kg bw per day 
(700 mg/kg bw per day) and using an uncertainty factor of 100, the acceptable daily intake 
(ADI) was 7 mg/kg bw per day. For an individual weighing 70 kg, this would represent a 
daily intake of 490 mg of L-aspartic acid. AESAN (2015) concluded that a maximum daily 
quantity of 490 mg of L-aspartic was acceptable from the safety point of view for use as a 
food supplement. In addition, it was noted that L-aspartic acid forms part of the habitual diet 
and is eaten as a component of the sweetener aspartame. 
Opinion on the re-evaluation of aspartame (E 951) as a food additive. European 
Food Safety Authority, EFSA, 2013 
Numerous intervention trials have been performed in adults with different aspartate 
compounds (sodium, magnesium, potassium-magnesium, buffered aspartic acid, and 
arginine aspartate) in doses ranging from 1 to 10 g/day, for time periods between one single 
dose and four weeks. None of these studies were undertaken to assess toxicity of aspartic 
acid intake. However, excluding reports on plasma amino acid imbalance and soft 
stools/diarrhea, no other adverse effects were reported. In neonatal rodents aspartate have 
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caused hypothalamic neuronal death, if given orally in large doses (500 mg/kg bw or higher) 
to infant animals (Olney, 1969; Olney and Ho, 1970; Lemkey-Johnson and Reynolds, 1974; 
Okaniwa et al., 1979; Finkelstein et al., 1983; Daabees et al., 1985 all cited in EFSA, 2013). 
A 90-day L-aspartic acid feeding study was performed by Tada et al., 2008. No signs or 
symptoms of neurotoxicity were observed at any of the doses tested. A NOAEL of 700 mg/kg 
bw/day for males was identified. The next higher dose gave renal toxicity findings (an 
apparent dose related regenerative renal tubules dilation in males accompanied by 
inflammatory cell infiltration). 
 Literature search 
Two systematic literature searches aiming at publications on adverse effects caused by L-
aspartic acid was performed in MEDLINE and EMBASE with no restriction on publication year. 
Both databases were searched to ensure comprehensive study retrieval. The search for 
human studies was conducted on 21 October 2016, and the search for animal studies was 
conducted 8 November, 2016. Both searches were limited to publications in English or 
Scandinavian languages. Conference abstracts, editorials and letters were not included in the 
searches. The search strategies are outlined in Appendix 1. 
2.1.2.1 Publication selection and data extraction 
The literature searches identified 2431 titles; 777 in the search for human studies and 1654 
in the search for animal studies. All titles and abstracts were screened against the following 
inclusion criteria:  
 An adverse effect/adverse effects in relation to L-aspartic acid alone is addressed 
 Route of exposure for humans is oral 
 Route of exposure for animals is oral, in addition, subcutaneous exposure is included 
if the toxicokinetics are equal as by oral exposure 
 Human studies are performed in apparently healthy individuals or patient groups 
assumed to have normal L-aspartic acid absorption and metabolism 
 Animal model studies address adverse effects relevant to human health 
In vitro studies were not included. 
The inclusion criteria checklist was developed by members of the Panel on Food Additives, 
Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics and the Panel on 
Nutrition, Dietetic Products, Novel Food and Allergy. Titles and abstracts that did not fulfil 
the inclusion criteria were excluded. Titles and abstracts of unclear relevance to the current 
risk assessment were retained for further review. The primary screening was performed 
independently by two Panel members. The publications that passed the primary screening 
were reviewed in full text against the same inclusion criteria by the author of this report. 
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The first screening of titles and abstracts of human studies identified 7 relevant publications 
for full-text review. Two additional human studies were identified in previous reports. After 
full-text review, all nine publications were considered not relevant and excluded.   
The first screening of titles and abstracts of animal studies identified 2 relevant publications 
for full-text review. Both of these were found relevant and included after full-text review. 
(see Figure 2.1.2.1-1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1.2.1-1: Flowchart for publication selection for L-aspartic acid. 
2.2 General information 
 Chemistry 
The molecular formula of L-aspartic acid is C4H7NO4 and the CAS number is 56-84-8. L-
aspartic acid has a molecular weight of 133.1 g/mol. The structural formula is shown in 
Main search 
The publications were identified searching 
Embase, Global Health, Medline and Web 
of Science 
Titles and abstracts 
n = 777 (human studies) 
n=1654 (animal studies) 
 
Full text 
n = 7 (human)  
n = 2 (animal) 
Manual search 
2 human studies 
were identified 
entified 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 9 (human)  
n = 0 (animal) 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 772 (human) 
n = 1652 (animal) 
Publication 
included: 
2 animal studies 
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figure 2.2.1-1. L-Aspartic acid is a dispensable dicarboxylic amino acid that can be produced 
by the transamination of oxaloacetic acid, an intermediate in the metabolism of e.g. glucose 
and some amino acids. In the presence of α-ketoglutarate, L-aspartic acid is converted to 
oxaloacetate and glutamate (Kohlmeier, 2015). 
 
Figure 2.2.1-1:  The structural formula of L-aspartic acid. 
 Occurrence 
All protein foods contain significant amounts of L-aspartic acid, thus total protein intake is a 
major determinant of L-aspartic acid intake. Relatively L-aspartic acid rich proteins are 
consumed with soybeans (124 mg/g total protein) and other legumes. Fish protein contains 
approximately 100 mg/g, eggs 100 mg/g, rice 94 mg/g, and most meats around 90 mg/g. 
Wheat protein contains only 50 mg/g (Kohlmeier, 2015). In the body, the Krebs-cycle 
intermediate oxaloacetate is the abundantly available precursor for L-aspartic acid. Aspartate 
aminotransferase uses the amino group from L-glutamate for synthesis of L-aspartic acid 
(Kohlmeier, 2015). The food sweetener aspartame is an exogenous source of L-aspartic acid, 
as it hydrolysed to aspartic acid, phenylalanine and minor quantities of methanol in the body 
(Stegink, 1976). Aspartame contains about 40% aspartic acid (EFSA, 2013). 
2.3 Absorption, distribution, metabolism and excretion (ADME) 
 Absorption and distribution 
Free amino acids and small peptides are absorbed nearly completely from the duodenum 
and jejunum. Free L-aspartic acid can enter intestinal cells via the XAG transport system. 
Thereafter it is transported to the liver for redistribution in the body. Most L-aspartic acid in 
blood is bound in proteins, and only minimal amounts circulate as free amino acids 
(Kohlmeier, 2015).  
 Metabolism and excretion 
The two major catabolic pathways of L-aspartic acid are transamination and utilisation of the 
resulting oxaloacetate, and utilisation in the urea cycle. A small amount of L-aspartic acid is 
directly converted to alanine by aspartic 4-decarboxylase in the liver and in the kidneys. In 
the first reaction, the transamination reaction, the PLP-dependent aspartate 
aminotransferase moves the amino group from L-aspartic acid to alpha-ketoglutarate, 
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producing glutamate. Both cytosolic and mitochondrial isoforms are abundant. Quantitatively 
minor transamination reactions are also catalysed by a few other coenzymes. The second 
step is the oxidative deamination of glutamate by the enzyme glutamate dehydrogenase, 
which takes place in the mitochondria. Consequently urea is formed. The oxaloacetate 
produced in the transamination may serve as a metabolite in the Krebs cycle and used for 
the production of glucose via gluconeogenesis (Kohlmeier, 2015). 
2.4 Toxicological data/Adverse effects 
 Animal studies 
Two relevant animal studies were identified and included in this risk assessment (Table 
2.4.1-1). 
Table 2.4.1-1: An overview of animal studies investigating L-aspartic acid and adverse health effects. 
Reference Animals Doses Main endpoints Duration 
of 
exposure 
Adverse 
effects 
NOAEL 
(mg/kg bw 
per day) 
Schieber et 
al., (1997) 
7 female SPF 
Sprague-
Dawley rats per 
group 
0 (control),  
50 mg/kg bw 
per day in 
drinking water 
Urinalysis, 
hematology, serum 
biochemistry, 
organ weights, 
gross- and 
histopathological 
examination 
28 days None Not 
addressed 
Tada et al., 
(2008) 
50 male and 50 
female Fischer 
344 rats (10 
per sex per 
group) 
Powder diet 
containing 0%, 
0.05%, 1.25%, 
2.5% and 
5.0% 
concentrations 
of aspartic acid 
Urinalysis, 
hematology, serum 
biochemistry, 
organ weights, 
gross- and 
histopathological 
examination 
90 days Toxic effects on 
kidneys 
(regenerative 
renal tubules 
with tubular 
dilation) (2.5% 
and 5.0% in 
males) 
Possible acinar 
cell hypertrophy 
of the 
submandibular 
and parotid 
glands (2.5% 
and 5.0% in 
both sex) 
M: 697 
F: 715 
Evaluation of D-amino acid levels in rat by gas chromatographyselected ion 
monitoring mass spectrometry: no evidence for subacute toxicity of orally fed D-
proline and D-aspartic acid, Schieber et al., 1997 
In this 28-day subacute toxicity study, seven Sprague-Dawley rats received deionised water 
(controls) while seven rats received drinking water with added L-aspartic acid corresponding 
to a mean daily load of approximately 50 mg L-aspartic acid/kg bw (Schieber et al., 1997). 
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After 28 days, the weights of the supposed target organs of toxicity (kidney, liver, brain, 
thymus) were determined and organs were inspected for macroscopic and microscopic 
alterations. No pathological changes in the organs were observed and no signs of subacute 
toxicity (liver, kidney) were found. The publication does not include any statement about 
whether the study was performed in accordance with official guidelines for testing of 
chemicals in animals. 
Toxic effects of L-aspartic acid at high dose levels on kidneys and salivary glands 
in Fischer 344 rats detected in a 90-day feeding study, Tada et al., 2008 
A subchronic oral toxicity study of L-aspartic acid was conducted with groups of 50 male and 
50 female Fischer 344 rats fed a powder diet containing 0%, 0.05%, 1.25%, 2.5% and 5.0% 
concentrations for 90 days (10 animals of each sex received each dose) (Tada et al., 2008). 
Serum biochemistry showed treatment-related decreases of blood urea nitrogen (2.5% or 
higher in males and in the 5.0% females), creatinine (5.0% or greater/higher males and of 
the 1.25% or greater/higher females) and uric acid levels (2.5% male and of the 1.25% or 
greater/higher females). In addition, incidences of urinary ketone and protein were 
significantly increased in treated animals of both sexes, while relative kidney weight was 
significantly increased in the 5.0% male rat. Regenerative renal tubules with tubular dilation 
were histopathologically observed in male rats of the 2.5% or greater groups. Acinar cell 
hypertrophy of salivary glands was histopathologically evident in male and female rats of the 
2.5% or greater groups. The results indicated that L-aspartic acid causes toxic effects on 
kidneys and possibly salivary glands at 2.5% and/or higher doses in male and female Fischer 
344 rats. The lowest observed adverse effect level (LOAEL) for L-aspartic acid in this study 
was thus defined by the 2.5% dose and corresponded to a consumed quantity of 1400 
mg/kg bw per day. The NOAEL was defined by the 1.25% dose, and corresponded to a 
consumed quantity of 696.6 mg/kg bw per day for males and 715.2 mg/kg bw per day for 
females. No signs suggesting neurotoxicity of L-aspartic acid were observed, and a specific 
neurotoxicity test was therefore not carried out. The authors discussed that neurotoxicity of 
the amino acid may be limited not only to the species level of rodent but also the age of the 
newborn. 
2.4.1.1 Interactions  
There was no information concerning interactions in the literature reviewed in the present 
risk assessment. The absence of information in the selected literature does not document an 
absence of interactions. 
2.4.1.2 Allergic sensitisation (including adjuvant effects) 
There was no information concerning allergic sensitisation or allergy adjuvant effects in the 
literature reviewed in the present risk assessment. The absence of information in the 
selected literature does not document an absence of allergic sensitisation or allergy adjuvant 
effects. L-aspartic acid per se would not be expected to behave as an allergen. 
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 Vulnerable groups 
Neonatal rodents are sensitive to the consumption of supplemental dicarboxylic amino acids 
since they lack the ability to metabolise the dicarboxylic amino acids (Stegink, 1976). The 
newborn rodent is particularly susceptible to brain lesions, and other dietary substances such 
as salt and sucrose has also produced brain lesions (Stegink, 1976). Administration of large 
quantities of glutamate and L-aspartic acid to newborn mice produces a variety of neurotoxic 
effects, the most marked of which is neuronal necrosis. This finding has, however, not been 
reproduced in neonatal nonhuman primates by a number of other scientists when giving 
either glutamate or aspartame at high dosages (EFSA, 2013). However, due to lack of long 
term studies on L-aspartic acid intake and possible negative health effects in humans, IOM 
(2005) concluded that aspartic acid dietary supplements are not advisable for infants and 
pregnant women. Neurotoxic effects of dicarboxylic amino acids in animal species other than 
newborn rodents are highly controversial, and the available data indicate little relevance to 
humans. In the present literature review, no studies with L-aspartic acid in children were 
found. There are no data indicating that children and adolescents are more vulnerable than 
adults for L-aspartic acid.  
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2.5 Summary of hazard identification and characterisation 
Literature searches including both human and animal studies have been conducted, in 
addition to reviewing previous reports (IOM, 2005; VKM, 2011). According to IOM (2005), all 
human and animal studies on the effects of aspartic acid were of short duration and there 
was a lack of dose-response data. The IOM (2005) therefore concluded that there are not 
sufficient scientific data to establish a UL for aspartic acid. The IOM (2005) noted that 
dietary supplement doses of up to 8 g/day (approximately 120 mg/kg bw per day) had not 
resulted in any documented adverse effects, however no reference was provided for this 
statement. 
Based on the systematic literature searches, we did not identify any long-term studies in 
healthy individuals that could be used for this risk assessment. In rats, a 90-day subchronic 
toxicity study by Tada et al. (2008) was identified, reporting a NOAEL of 697 mg/kg bw per 
day in males and 715 mg/kg bw per day in females. A LOAEL was identified at 1400 mg/kg 
bw day with toxic effects on the kidneys (regenerative renal tubules dilation accompanied by 
inflammatory cell infiltration) and acinar cell hypertrophy of salivary glands. 
In summary, the following information is considered in the current assessment: 
 No long-term studies on L-aspartic acid in healthy children, adolescents or adult 
humans were found. 
 Short-term human studies found no adverse health effect when L-aspartic acid was 
given in acute doses ranging from 1 to 10 g for time periods between one single dose 
and four weeks. These studies were however not designed to assess toxicity of L-
aspartic acid.  
 Administration of large quantities of L-aspartic acid to newborn mice has produced a 
variety of neurotoxic effects, the most marked of which was neuronal necrosis. 
Neurotoxic effects of dicarboxylic amino acids in animal species other than newborn 
rodents are highly controversial, and the available data indicate little relevance for 
humans.  
 A 90-day subchronic toxicity study in rats, with a NOAEL of 697 mg/kg bw per day in 
males and 715 mg/kg bw per day in females was identified. No neurotoxicity was 
found, however a toxic effect on kidneys and possibly salivary glands was observed 
at 1400 mg/kg bw per day (LOAEL).  
For the risk characterisation (chapter 4), the NOAEL of 697 mg/kg bw per day derived from 
the abovementioned subchronic toxicity study in rats is used for comparison with the 
estimated exposures from food supplements.  
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3 Exposure / Intake 
The exposure to L-aspartic acid was estimated for the doses received by the NFSA for the 
age groups children (10 to <14 years), adolescents (14 to <18 years) and adults (≥18 
years).  
3.1 Food supplements 
The Norwegian Food Safety Authority requested VKM to perform a risk assessment of 3000, 
3500, 4000, 4500, 5000 and 5700 mg/day L-aspartic acid in food supplement for children 
(10 – 17 years) and adults. The default body weights for age groups determined by EFSA 
were used: 10 to <14 years = 43.4 kg, 14 to <18 years = 61.3 kg and adults = 70.0 kg. The 
exposures per kg bw are given in Table 3.1-1. 
Table 3.1-1: Estimated exposure of L-aspartic acid from specified doses in food supplements in 
children, adolescents and adults. 
Groups Daily doses  
(mg) 
Body weight 
(kg) 
Exposure  
(mg/kg bw per day) 
Children (10 to <14 years) 3000, 3500, 4000, 
4500, 5000 and 5700 
43.4 69, 81, 92, 104, 115 and 
131 
Adolescents (14 to <18 years) 3000, 3500, 4000, 
4500, 5000 and 5700 
61.3 49, 57, 65, 73, 82 and 93 
Adults (≥18 years) 3000, 3500, 4000, 
4500, 5000 and 5700 
70.0 43, 50, 57, 64, 71 and 81 
3.2 Other sources 
Based on the NHANES III (1988-1994), the overall mean intake of L-aspartic acid from food 
and food supplements in the United States was 6.5 g/day (IOM, 2005). Men 31 through 50 
years of age had the highest intake at the 99th percentile of 15.4 g/day. 
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4 Risk characterisation  
The doses received from the NFSA for assessment were 3000, 3500, 4000, 4500, 5000 and 
5700 mg/day L-aspartic acid in food supplements, and the estimated exposures for adults, 
adolescents and children 10 years and older derived from these dose levels are given in 
chapter 3. 
The NOAEL used in this report is 697 mg/kg bw per day derived from a 90-day subchronic 
toxicity study in rats (Tada et al., 2008). The margins of exposure (MOE) between the 
NOAEL of 697 mg/kg bw per day and the exposure of L-aspartic acid from food supplements 
are presented in Table 4-1. 
Table 4.-1: The calculated margins between NOAEL (697 mg/kg bw per day) from an animal 
study, and the exposure to L-aspartic acid from food supplements (MOE-values) for the various age 
groups. 
Age groups 3000 
mg/day 
3500 
mg/day 
4000 
mg/day 
4500 
mg/day 
5000 
mg/day 
5700 
mg/day 
Children (10 
to <14 
years) 
(43.4 kg) 
10 9 8 7 6 5 
Adolescents 
(14 to <18 
years) 
(61.3 kg) 
14 12 11 10 9 8 
Adults (≥18 
years) 
(70 kg) 
16 14 12 11 10 9 
The calculated MOE-values for the NOAEL from the animal study ranged from 5 to 16 for a 
daily intake of 3000 to 5700 mg/day of L-aspartic acid. 
These low MOE-values are not regarded as acceptable since L-aspartic acid has caused toxic 
effects on the kidneys (regenerative renal tubules with tubular dilation) and acinar cell 
hypertrophy of salivary glands in rats and direct information on the potential adverse health 
effects in humans is not available due to an absence of long-term studies.  
No studies with L-aspartic acid in children were found. There are no data indicating that 
children and adolescents are more vulnerable than adults for L-aspartic acid. No tolerance 
level is set for L-aspartic acid specifically for children or adolescents.  
VKM considers that: 
In adults (≥18 years), the specified doses 3000, 3500, 4000, 4500, 5000 and 5700 mg/day 
L-aspartic acid in food supplements may represent a risk of adverse health effects.  
  
VKM Report 2017:11  25 
In adolescents (14 to <18 years), the specified doses 3000, 3500, 4000, 4500, 5000 and 
5700 mg/day L-aspartic acid in food supplements may represent a risk of adverse health 
effects.  
In children (10 to <14 years), the specified doses 3000, 3500, 4000, 4500, 5000 and 
5700 mg/day L-aspartic acid in food supplements may represent a risk of adverse health 
effects.  
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5 Uncertainties 
For the current risk assessment there are potentially large uncertainties arising from: 
 The lack of relevant human data available for risk characterisation 
 The risk characterisation being based on a 90-day (subchronic) study in rats – species 
extrapolation 
 The lack of knowledge about habitual daily dietary intake of L-aspartic acid in Norway 
The assumption that children and adolescents have similar tolerance as adults relative 
to their body weight, due to lack of data 
 The possible failure of the systematic literature search, based on the predefined search 
criteria, to identify relevant literature reporting adverse effects of L-aspartic acid in 
humans or animals 
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6 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-aspartic acid in food supplements at the 
doses 3000, 3500, 4000, 4500, 5000 and 5700 mg/day for the general population, ages 10 
years and above. The specific doses were not regarded as acceptable since L-aspartic acid 
has caused toxic effects on the kidneys (regenerative renal tubules with tubular dilation) and 
acinar cell hypertrophy of salivary glands in rats and information of the potential adverse 
health effects in human is unknown due to lack of long-term studies. 
VKM concludes that: 
 In adults (≥18 years), the specified doses 3000, 3500, 4000, 4500, 5000 and 
5700 mg/day L-aspartic acid in food supplements may represent a risk of adverse 
health effects.  
 In adolescents (14 to <18 years), the specified doses 3000, 3500, 4000, 4500, 5000 
and 5700 mg/day L-aspartic acid in food supplements may represent a risk of 
adverse health effects.  
 In children (10 to <14 years), the specified doses 3000, 3500, 4000, 4500, 5000 and 
5700 mg/day L-aspartic acid in food supplements may represent a risk of adverse 
health effects.  
An overview of the conclusions is presented in Table 6-1.  
Table 6-1 An overview of the conclusions on L-aspartic acid in food supplements. 
Red: estimated exposure may represent a risk of adverse health effects. 
 
L-aspartic acid 
Food 
supplement 
 
Age groups 
3000 
mg/day 
3500 
mg/day 
4000 
mg/day 
4500 
mg/day 
5000 
mg/day 
5700 
mg/day 
Children 
(10 to <14 
years) 
      
Adolescents 
(14 to <18 
years) 
      
Adults 
(18 years) 
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7 Data gaps 
 There is a lack of long-term studies on L-aspartic acid in healthy children, adolescents 
and adult humans 
 There are few toxicological studies in animals where L-aspartic acid is provided as a 
single supplement and with an appropriate study design to investigate possible long-
term adverse effects 
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9 Appendix 
Search strategy for human studies 
Database: Embase <1974 to 2016 October 20>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. aspartic acid*.ti. (4359) 
2. aspartat*.ti. (23958) 
3. 1 or 2 (28272) 
4. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (10379211) 
5. 3 and 4 (5506) 
6. (conference abstract* or letter* or editorial*).pt. (5202828) 
7. 5 not 6 (5333) 
8. limit 7 to (danish or english or norwegian or swedish) (5198) 
9. limit 8 to human (1263) 
10. remove duplicates from 9 (777) 
Search strategy for animal studies 
1. Database: Embase <1974 to 2016 November 07>, Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
2. aspartic acid*.ti. (4356) 
3. aspartat*.ti. (23917) 
4. 1 or 2 (28228) 
5. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (10411790) 
6. 3 and 4 (5511) 
7. (conference abstract* or letter* or editorial*).pt. (5215921) 
8. 5 not 6 (5331) 
9. limit 5 to (danish or english or norwegian or swedish) (5376) 
10. limit 8 to animals (2694) 
11. remove duplicates from 9 (1654) 
